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Viral replication alters gene expression and 
protein metabolism in host cells. This perturbs 
the profi  le of proteins displayed on the plasma 
membrane, labeling infected cells as abnormal 
and targeting them for destruction by cytotoxic 
eff  ectors. Such perturbations fall into two cate-
gories: the display of pathogen-encoded mole-
cules and the altered expression of host-encoded 
markers, including diverse members of the MHC 
class I superfamily (MHCISF). The former are 
sensed using clonotypic receptors of adaptive 
immunity, whereas the latter are sensed through 
receptors associated with innate immunity.
NKG2D is an activating receptor of NK lym-
phocytes, as well as of species-specifi  c subsets of 
T lymphocytes (for review see reference 1). It 
binds host-encoded members of the MHCISF 
whose expression is enhanced by extracellular 
signals and intracellular metabolic disturbances, 
particularly those resulting from infection (for re-
view see reference 1). Human and mouse CMV 
encode MHC class I–like proteins that block cell-
surface expression of NKG2D ligands (2–7). By 
interfering with NKG2D-dependent responses 
to infected cells, these proteins permit enhanced 
replication of the virus in a hostile immunologic 
environment. Conservation of the corresponding 
genes by wild strains of CMV (unpublished data) 
demonstrates, prima facie, the importance of 
NKG2D-mediated immunity to CMV evolution.
In this paper, we show that zoonotic ortho-
poxviruses (ZPXVs) encode a secreted class 
I–like competitive antagonist of NKG2D, sug-
gesting that NKG2D function also applies se-
lective pressure to these viruses. In contrast to 
CMV, ZPXVs have adapted the class I domain 
fold to target the receptor rather than its ligands. 
Because receptors that direct innate cytotoxic-
ity against epidemiologically relevant orthopox-
viruses remain undefi  ned, this fi  nding should 
open new avenues of research into immunity 
against these emerging pathogens.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Hidden Markov model (HMM) analysis reveals 
an orthopoxvirus MHC class I–like 
protein (OMCP)
NKG2D ligands adopt MHC class I–like back-
bone folds despite low sequence identity (for 
review see reference 8). The m157 protein of 
mouse CMV (a ligand for the Ly49H NK re-
ceptor) probably does so as well, though the Basic 
Local Alignment Search Tool heuristic fails to 
align it with any mammalian member of the 
MHCISF (9, 10). We hypothesized that ortho-
poxviruses also encoded MHCISF proteins that 
remained undetected because of their extreme 
sequence divergences. Indeed, uncharacterized 
class I–like open reading frames in the genomes of 
molluscipoxvirus, suipoxvirus, and  yatapoxviruses 
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have been predicted using local alignment methods (for review 
see reference 11). To search for the former, we adapted the 
profi  le HMM algorithm embodied in the Sequence Alignment 
and Modeling (SAM) software package from the University 
of California, Santa Cruz (12, 13).
To avoid bias toward classical class I sequences, we used 
a seed alignment consisting only of divergent class I–like plat-
form domains; during iterative model weighting, this was 
left inviolate despite the eventual inclusion of classical class I 
sequence information. To avoid alignment errors arising from 
the small number of available highly divergent MHCISF 
members, this seed was based on secondary structure defi  ned 
by x-ray diff  raction.
A search of National Center for Biotechnology Informa-
tion (NCBI) raw viral sequence data yielded high-scoring 
translations encoded within the genomes of cowpox virus 
(CPXV; available from GenBank/EMBL/DDBJ under ac-
cession nos. AF482758 and X94355) and monkeypox virus 
(MPXV; available from GenBank/EMBL/DDBJ under ac-
cession no. NC_003310.1). None were found in the vac-
cinia or variola genomes. In every case, the corresponding 
open reading frames lay within genomic fl  anking regions, 
the sites of poxvirus immunomodulatory loci (for review see 
reference 11). These sequences correspond to a single pro-
tein (OMCP) with four variants, the fi  rst encoded by less 
virulent West African MPXV (clade-1) (14, 15), the second 
encoded by the more virulent Central African MPXV (clade-2) 
(14, 15), the third encoded by CPXV-GRI90, and the fourth 
encoded by CPXV–Brighton Red (CPXV-BR; Fig. 1 A). 
Clade-1 MPXV possess identical functional copies at both 
fl  anks of their genomes, whereas clade-2 viruses possess only 
a right-sided functional copy, with the left-sided one being a 
nonfunctional fragment (not depicted). Consistent with the 
proposal that CPXV-BR represents a distinct orthopoxvirus 
species (16), Brighton Red OMCP is considerably more di-
vergent from the other sequences than they are from each 
other. Because of the >93% aa identity between the fi  rst three 
variants, they henceforth are collectively termed OMCPMPX. 
The Brighton Red variant henceforth is termed OMCPBR.
OMCP possesses a strongly predicted leader sequence, 
two cysteines (Fig. 1 A), and a common potential N-linked 
glycosylation site at Asn31 (CPXV-BR numbering); OMCPBR 
has a second potential N-linked site at Asn107 (Fig. 1 A). 
Backbone prediction using the FUGUE (17) threading algo-
rithm assigns reasonable likelihood (z-score >5) to a class I–
like fold for OMCP. In this model, the cysteines are close in 
three-dimensional space (Fig. 1 B) and are predicted to form 
a disulfi  de bond. Neither transmembrane spans nor GPI 
transamidation sites could be predicted in any reading frame 
near the ends of the coding sequences, suggesting OMCP to 
be a secreted protein. To test this, supernatants from both 
mock-infected B-SC-1 cells as well as those infected either 
with CPXV-BR or Western Reserve vaccinia virus (VV) 
were screened by immunoblot for reactivity with a polyclonal 
Figure 1.  OMCP is likely a secreted class I–like protein. (A) Multiple 
alignment of the four OMCP variants. Cysteines (C) and potential N-linked 
glycosylation sites (closed circles) are indicated. (B) Backbone model of 
OMCPBR derived by threading through the RAE1β structure (closed squares, 
cysteines). Similar results were obtained for OMCPMPX. (C) Immuno  blot of 
culture media conditioned by mock-infected and CPXV-BR–infected 
B-SC-1 cells suggests secretion of OMCP. (D) Immunoblot showing that 
brefeldin A, but not its ethanol vehicle, prevents the appearance of 
OMCPBR in supernatants from infected OP9 cells (far right lane vs. second 
lane from right). Brefeldin A also causes the accumulation of OMCP in 
lysates of treated cells (third lane from left).JEM VOL. 204, June 11, 2007  1313
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antiserum against recombinant OMCPBR (Fig. 1 C). Only 
supernatants from CPXV-BR–infected cells reacted with the 
antiserum, while neither supernatant reacted with preim-
mune serum. To verify that OMCP was secreted and not re-
leased from lysed cells, CPXV-BR–infected OP9 cells were 
treated with nothing, vehicle alone, or brefeldin A (Fig. 1 D). 
Treatment with brefeldin A, but not its ethanol vehicle, pre-
vented OMCP reactivity from appearing in the superna-
tant. Accordingly, OMCP accumulated in brefeldin A–treated 
cell lysates. No supernatant reacted with preimmune serum. 
The basis of the two OMCP bands secreted by OP9 cells 
is unknown.
Figure 2.  OMCP binds huNKG2D and muNKG2D. (A) Ba/F3 cells 
expressing EGFP only (top), huNKG2D (middle), or muNKG2D (bottom) 
were treated with nothing, SA-PE, or fl  uorescent tetramers. (B) Ba/F3 
cells transduced with huNKG2D or muNKG2D were incubated with anti-
NKG2D mAb, isotype-matched mAb, irrelevant soluble protein, or soluble 
ligand before staining with OMCPBR (rows 1 and 3) or OMCPMPX (rows 
2 and 4) tetramers. (C) Ba/F3 cells transduced either with Thy1.1 (top) 
or OMCP-Thy1.1 (middle and bottom) were treated with SA-APC or fl  uo-
rescent tetramers. Untransduced (nongreen) Ba/F3 cells were included 
as internal standards in A–C. Transduction vectors are dicistronic, with 
EGFP in the second cistron. (D, 1) SPR assay of OMCPBR (0, 2, 5, 10, 20, 50, 
100, 200, 500, and 1,000 nM) binding to immobilized muNKG2D. The 
horizontal bar represents the OMCP injection, and the star represents the 
time point used for KD fi  tting. (D, 2) Nonlinear curve fi  tting of steady-
state SPR data reveals high affi  nity for muNKG2D and a good coeffi  cient 
of determination for the fi  t. (D, 3) One representative experiment out 
of four showing kinetic data (black lines) and global fi  t (gray lines) of 
OMCPBR (5, 10, 20, 50, and 100 nM) binding to muNKG2D. (D, 4) One repre-
sentative experiment out of six showing kinetic data (black lines) and 
global fi  t (gray lines) of OMCPBR (0.32, 0.63, 1.25, and 2.5 nM) binding 
to huNKG2D. Note the very different dissociation kinetics between the 
data in 3 and 4.1314  ORTHOPOXVIRUS NKG2D ANTAGONIST | Campbell et al. 
Because it is not associated with a cell membrane, OMCP 
cannot cluster its cognate receptor. Making the assumption 
that most ZPXV immunomodulating proteins are immuno-
suppressive, we hypothesized that OMCP binds an activating 
receptor, acting as a competitive antagonist.
OMCP binds to NKG2D with high affi  nity
Because NKG2D ligands adopt a class I–like fold (for review 
see reference 8), we tested whether NKG2D is a receptor for 
OMCP. To this end, Ba/F3 cells were transduced with de-
fective dicistronic retroviruses encoding human NKG2D 
(huNKG2D) and enhanced GFP (EGFP), mouse NKG2D 
(muNKG2D) and EGFP, or EGFP alone. The NKG2D ecto-
domain was spliced to Ly49A transmembrane and intra-
cellular domains to avoid the need for a signaling chain. 
Transductants were then treated with fl  uorescent tetramers 
and analyzed by fl  ow cytometry. OMCP tetramers, but nei-
ther streptavidin-PE (SA-PE) alone nor irrelevant tetramers, 
stained these transductants (Fig. 2 A, middle and bottom 
rows). No tetramers stained EGFP-only transductants (Fig. 
2 A, top row). Preincubation either with mAb against NKG2D 
or with recombinant NKG2D ligands inhibited the inter-
actions between OMCP tetramers and NKG2D transductants; 
however, preincubation either with isotype control mAb or 
with irrelevant recombinant protein failed to inhibit these in-
teractions (Fig. 2 B). The origin of two distinct transductant 
populations in certain purifi  ed cell preparations is unclear. To 
exclude an artifact arising from a joint binding surface pre-
sented by OMCP and SA, the inverse experiment was also 
performed. muNKG2D tetramers stained Ba/F3 transduc-
tants expressing chimeric OMCP-Thy1.1 on the cell surface 
but not cells expressing only Thy1.1 (Fig. 2 C). Thus, OMCP 
is a virally encoded NKG2D ligand.
We hypothesized that OMCP blocks the interaction be-
tween NKG2D and its target cell–expressed ligands. If so, it 
should bind NKG2D with high affi   nity to overcome the 
multivalency of cell-surface ligands at reasonable protein 
concentrations. We performed surface plasmon resonance 
(SPR) studies to determine the binding parameters of this 
interaction, assuming a 1:1 binding model for (NKG2D)2/
OMCP. The KD of OMCPBR for immobilized muNKG2D 
was 37 ± 6 nM (n = 3) by steady-state analysis at 20°C, 
pH 7.5, and 150 mM NaCl (Fig. 2 D, 2). KD calculated from 
kinetic analysis (i.e., KD = koff  /kon; Fig. 2 D, 3) was similar: 
28 ± 4 nM, with koff   = 1.8 ± 0.1−2 s−1 and kon = 6.8 ± 1.2 × 
105 M−1s−1 (n = 4). These parameters are akin to those of the 
higher affi   nity muNKG2D ligands H60 and RAE1ε (18, 19). 
Curiously, affi   nity of OMCPBR for huNKG2D was strikingly 
higher: KD = 168 ± 33 pM (n = 6), with the diff  erence 
largely caused by the lower koff   (1.23 ± 0.12 × 10−4 s−1; Fig. 
2 D, 4). Analogous experiments with OMCPMPX were not 
performed because of the inability to obtain consistent specifi  c 
activity of the recombinant protein.
Next, C57BL/6 (B6) splenocytes were costained with NK 
markers and OMCPBR tetramers (Fig. 3 A). NK and NKT 
cells bound OMCPBR tetramers. Pretreatments with either 
anti-muNKG2D mAb (Fig. 3 A, lines 6) or the muNKG2D 
ligand MULT1 (lines 8) inhibited binding to both cell types; 
treatments with an isotype-matched mAb (lines 5) or an ir-
relevant protein had no eff  ect (lines 7). Consistent with the 
lack of NKG2D expression on resting mouse T cells (20), 
OMCPBR tetramers failed to bind freshly isolated splenic T 
cells. Splenocytes from three other strains of mice and (within 
the limitations imposed by a lack of validated reagents) rats, 
hamsters, guinea pigs, and voles also exhibited similar staining 
with OMCPBR (unpublished data). This argues for the relevance 
Figure 3.  OMCP binds to mouse and human leukocyte subpopu-
lations. (A) B6 splenocytes were stained with mAbs against NK markers 
and OMCPBR tetramers. OMCPBR staining of cells in each gate is indicated 
in histograms. Each histogram group shows unstained cells (lines 1), 
cells stained with SA-APC alone (lines 2), irrelevant tetramers (lines 3), 
OMCPBR tetramers (lines 4), or OMCPBR tetramers after pretreatment with 
50 μg/ml of irrelevant hamster IgG (lines 5), equimolar anti-muNKG2D 
(lines 6), 9.5 μM of irrelevant protein (lines 7), or equimolar MULT1 
(lines 8). (B) Human PBMCs were stained with NK or T cell marker mAbs 
and were tested for OMCP binding, as in A, for lines 1–4. Pretreatments 
with 50 μg/ml of mouse IgG1 (lines 5) or equimolar anti-huNKG2D 
mAb (lines 6) were also performed before staining with tetramers. Repre-
sentative experiments are shown (n = 4). Vertical lines in histograms 
represent the 99th percentile of staining for irrelevant tetramer-
stained cells.JEM VOL. 204, June 11, 2007  1315
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of this work to rodents generally and the reservoir hosts of 
ZPXV in particular (21, 22).
To explore the potential relevance of OMCP to orthopox 
zoonoses, human PBMCs were tested for binding to OMCPBR 
tetramers. Binding to human cells was essentially the same as 
that to mouse cells, except that fresh CD8+ T cells bound 
OMCPBR (Fig. 3B), consistent with the known expression of 
NKG2D on these cells. Analogous to mouse splenocytes, 
OMCP binding to human NK and NKT cells was blocked 
by anti-huNKG2D mAb (Fig. 3 B, lines 6). Cumulatively, 
these fi  ndings indicate that OMCP binds to NKG2D with 
high affi   nity and in a manner competitive with the endoge-
nous ligands of this receptor.
OMCP inhibits NKG2D-dependent killing as a 
soluble antagonist
51Cr killing assays were performed using B6 lymphokine–
  activated NK cells against RMA target cells. Control vector–
transduced RMA cells are relatively resistant to killing by 
B6 NK cells because of syngeneic MHC class I expression 
(Fig. 4 A, open squares) (23, 24). Expression of H60 by RMA 
cells enhanced their susceptibility to killing by activated NK 
cells in an NKG2D-dependent fashion (circles). NKG2D speci-
fi  city was verifi  ed by inhibition of killing upon addition of 
the high-affi   nity muNKG2D ligand MULT1 to the reaction 
(unpublished data) (23). Recombinant OMCPBR at concen-
trations from 100 nM to 1 μM (open and closed triangles, 
  diamond, and closed squares) blocked RMA-H60 killing, 
whereas 1 μM of irrelevant recombinant protein did not (Fig. 
4 A, X). Similar results were obtained with fresh NK cells (not 
depicted). This eff  ect was not caused by down-regulation of 
NKG2D, as exposure of B6 NK cells to 1 μM OMCPBR had 
no eff  ect on NKG2D expression (Fig. 4 B, lines 3 and 6).
OMCP is likely a paracrine inhibitor of NKG2D function
OMCP binds NKG2D in a manner preventing recognition of 
host ligands. This may be an important immune evasion strategy 
during ZPXV infections. Given an adequate local OMCP 
concentration around infected cells, inhibitory conditions 
analogous to those in the killing assay of Fig. 4 A might be 
attained. To measure the amount of OMCP produced   during 
infection, semiquantitative immunoblotting of infected cell 
supernatants was performed using recombinant OMCP as a 
Figure 4.  OMCP inhibits muNKG2D-dependent killing by activated 
NK cells but does not down-regulate NKG2D. (A) B6 IL2-activated NK 
cells were used as cytotoxic effectors against transduced RMA cells in 4-h 
51Cr release assays at effector/target ratios of 1:1, 3:1, or 10:1. There was 
minimal killing of EGFP-only transductants (open squares). There was 
effective NKG2D-dependent killing of H60 transductants (circles), but 1 μM 
of irrelevant protein failed to inhibit NKG2D-dependent killing (X). How-
ever, OMCPBR at 1 (closed squares), 0.5 (diamond), 0.25 (closed triangle), 
and 0.1 μM (open triangle) did effectively inhibit NKG2D-dependent 
killing. Error bars were omitted to avoid crowding; coeffi  cients of variation 
for all data points were <10%. (B) B6 splenocytes were cultured for 24 h 
with 1 μM of irrelevant protein (lines 1–3) or 1 μM OMCPBR (lines 4–6) 
and stained with nothing (lines 1 and 4), isotype-matched mAb (lines 2 
and 5), or anti-muNKG2D (lines 3 and 6). All histograms are gated on live, 
CD3−, NK1.1+ cells. No differences in the scatter properties or viability of 
cells was noted (not depicted). (C) Immunoblotting of OMCP was per-
formed with known amounts of recombinant protein (left blot) or CPXV-
infected OP9 supernatants (right blot). The former was used to quantitate 
the latter using a linear fi  t of OMCP densitometry to quantity (plot), as 
  detailed in Materials and methods. One experiment out of three is shown. 
Xs represent mean calibration data, dots represent supernatant data, the 
continuous line represents linear fi  t, and the dotted lines bound the 95% 
confi  dence interval. (D) Ba/F3 cells were treated either with mock viral (left) or 
CPXV-BR (right) preparations for 24 h. Cells were stained with nothing (lines 1), 
SA-PE (rows 2), control tetramers (rows 3), or muNKG2D tetramers alone 
(rows 4), as well as with 7-amino-actinomycin D. NKG2D binds infected cells, 
indicating up-regulation of NKG2D ligands by CPXV-BR infection. The 
  percentage of positive cells corresponds to the percentage of productively 
infected cells (not depicted). Vertical lines in the histograms (B and D) repre-
sent the 99th percentile of staining for irrelevant tetramer-stained cells.1316  ORTHOPOXVIRUS NKG2D ANTAGONIST | Campbell et al. 
standard (Fig. 4 C). Protein was secreted at an average rate of 
 3,000 copies/cell/s during the viral incubation time. As-
suming diff  usion constants in interstitial fl  uid and basement 
membrane of  10−7 and 5 × 10−9 cm2s−1, respectively (25), 
this secretion rate reasonably allows inhibitory concentrations 
of OMCP to develop around infected cells in situ given the 
KD values of the NKG2D–OMCP interaction (26). We thus 
propose a model in which secreted OMCP acts in paracrine 
fashion to competitively antagonize the inter  action between 
NKG2D on cytotoxic eff  ectors and induced ligands on infected 
targets (Fig. 4 D). Because eff  ective NKG2D cross-linking 
cannot then take place, activation signals promoting granule 
release are blunted, prolonging viral replication in infected 
cells. This, especially at mucosal sites and in the skin, increases 
the odds of transmission to another host, enhancing viral fi  tness. 
Though NKG2D ligands shed into serum may cause systemic 
receptor down-regulation (27), we disfavor this mode of action 
for OMCP because soluble OMCP fails to down-regulate 
NKG2D on mouse NK cells (Fig. 4 B).
Although certain virally encoded molecules are known to 
impair NKG2D-mediated detection of infected cells (2–7), 
OMCP is the fi  rst to target the receptor itself rather than its 
ligands. Of greater note, OMCP serves as a pointer to a recep-
tor specifi  cally important to the interactions between ZPXV 
and their hosts, guiding future studies of intercellular recogni-
tion events underlying cytotoxic immunity to these viruses.
MATERIALS AND METHODS
HMM analysis of sequences. The SAM software package (version 3.4) was 
installed on a workstation running Redhat Linux 9. SAM is extensively doc-
umented at http://www.cse.ucsc.edu/research/compbio/papers/sam_doc/.
Using structural models of RAE1 (1jfm), ULBP3 (1kcg), MICA (1b3j), 
MICB (1je6; for review see reference 8), and MULT1 (Fremont, D., personal 
communication), multiple sequence alignment based on secondary structural 
boundaries was generated and used as a seed for the target2k script with match 
positions as constraints. Target2k in superfamily mode was applied to the 
NCBI nr protein database. This alignment was then used by the buildmodel 
script to produce HMMs of divergent class I–like protein sequences.
To tune parameters of the buildmodel and hmmscore procedures, a test 
set of 26,000 irrelevant mouse cDNA sequences spiked with the cDNAs 
encoding H60, m157, m154, and mill-1 was used. Parameters were chosen 
based on assignment of lower expect values to the four spiked sequences than 
to non–MHC-like sequences. The fi  nal model was built using w0.5 (global 
scoring for model construction) default parameters. Sequence scoring was 
ultimately performed using -sw2 (local) mode with a reverse-sequence null 
model on reading frames >60 aa from raw genomic sequences of all viruses 
(except CMV) available from the NCBI virus genome database as of February 
2004. Sequence alignment was performed in SAM and formatted using 
BoxShade software (version 3.2; available at http://www.ch.embnet.org/
software/BOX_doc.html).
Molecular cloning, expression, refolding, and SPR analysis of NKG2D 
and mature OMCP. OMCPMPX (N3R; available from GenBank/EMBL/
DDBJ under accession no. NC_003310) and OMCPBR (V018; available 
from GenBank/EMBL/DDBJ under accession no. AF482758) coding se-
quences were amplifi  ed from monkeypox Zaire 1979 DNA and CPXV-BR 
DNA, respectively. Amplicons excluded the predicted leaders (Fig. 1) but 
included C-terminal biotin ligase tags. Cloning and expression was per-
formed as previously reported (19). OMCP and muNKG2D refolding, pu-
rifi  cation, biotinylation, characterization, and SPR analysis took place as 
previously described (19), except that the refolding time was extended to 
>72 h. A huNKG2D protein from ...ESYCG to the C terminus, fused to 
an N-terminal BirA tag, was similarly produced, except that refolding was 
performed in 2.5 M proline/0.1 M Tris-Cl, pH 7.2/0.01% Na-azide/5 mM 
of reduced glutathione/0.5 mM of oxidized glutathione, as previously 
described (28). Regeneration of the huNKG2D/OMCP SPR chips was 
performed using 30-s injections of 170 μM Triton X-100/0.5 M LiCl/20 mM 
Na-citrate, pH 4.8.
Mice and cell culture. C57BL/6 mice were obtained from the National 
Cancer Institute. RMA, Ba/F3, and activated NK cells were used as previ-
ously described (23, 29). B-SC-1 monkey kidney cells and OP9 marrow 
  fi  broblastic cells were obtained from American Type Culture Collection. 
Mouse work was approved by the Animal Studies Committee.
Retroviral constructs and generation of transduced cell lines. 
HuNKG2D-expressing cells were produced by amplifying the huNKG2D 
ectodomain sequence from FNQEV... to ...MQRTV, the muNKG2D ecto-
domain sequence from ...KETFQ to ...MKRAV, and the Ly49A trans-
membrane and intracellular domains from MSEQE... to ...SVLAI, with 
primers such that the NKG2D N-termini overlapped with the Ly49A C ter-
minus, and vice versa. These PCR products were PCR-spliced to produce 
chimeric NKG2D-Ly49A. For OMCP-expressing cells, OMCP was fused 
to the mature N terminus of Thy1.1. Full-length OMCPBR and OMCPMPX 
were amplifi  ed with primers encoding a C-terminal linker of Ser(Gly)4Ser. 
Thy1.1 was amplifi  ed from sequence QKVT... to ...DFISL. Primers ampli-
fying the OMCP C termini overlapped with the N-terminal Thy1.1 primer, 
and vice versa, allowing these amplicons to be spliced together. Full-length 
Thy1.1 was amplifi  ed from sequence MNPAI... to ...DFISL. Amplicons 
were used to produce retrovirally transduced cell lines sorted to homogene-
ity for expression of the transgenes, as previously described (23).
Antibodies and antiserum. The following antibodies were purchased 
from eBioscience: anti-CD3 PE-Cy5, anti-CD4 FITC, mouse IgG1, anti-
muNKG2D–allophycocyanin (APC; clone CX5), and rat IgG1-APC. Anti-
CD3 FITC, anti-CD8 PE, anti-CD3 CyChrome, anti-CD56 PE, anti-NK1.1 
PE, and anti-huNKG2D (clone 1D11), and hamster IgG were purchased 
from BD Biosciences. Anti-muNKG2D (clone 3C7) has been previously 
described (29). Rabbit OMCPBR antiserum was obtained from Washington 
Biotechnology after immunization with refolded OMCPBR.
Viruses. CPXV-BR and VV were obtained from American Type Culture 
Collection and were propagated in B-SC-1 cells using standard techniques.
Western blot analyses. 0.5 × 106 B-SC-1 cells/sample were infected with 
CPXV-BR and/or VV at 5 PFU/cell in 1 ml of medium. The supernatant was 
collected at 24 h, centrifuged at 13,000 g for 10 min, mixed with loading 
buff  er, resolved by SDS-PAGE, and transferred to nitrocellulose using standard 
techniques. Membranes were incubated with 1:2,000 dilutions of OMCPBR 
antiserum, preimmune serum, or anti–mouse actin (Chemicon), followed by 
0.5 μg/ml of horseradish peroxidase–labeled goat anti–rabbit Ig antibody and 
visualized with enhanced chemiluminescence (GE Healthcare).
Measurement of OMCP secretion was performed in sixwell plates by 
infection of 300,000 OP9 cells with CPXV-BR (multiplicity of infection = 5) 
for 20 h (>90% infected though intact cells at this point) in 0.85 ml of 
medium. Immunoblots of culture supernatants and recombinant OMCP 
standards were measured directly by fl  uorescence densitometry on a scanner 
(Typhoon Trio) using ImageQuant software (both from GE Healthcare) and 
uniform image rectangle background subtraction. Data of triplicate standards 
were fi  t to a linear model of antibody binding to blotted OMCP using Prism 
software (version 4; GraphPad) to obtain a standard line. Three experiments 
with independent standards and infections, each in triplicate, were plotted 
onto these lines to obtain the mean ± SD mass of OMCP secreted. Synthesis 
rate (copies per second) was obtained from secreted mass as follows: rate = 
mass × (NA)/[(20 h × 3,600 s/h) × (m.w.OMCP)].JEM VOL. 204, June 11, 2007  1317
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Flow cytometry. B6 splenocytes were RBC cleared and passed through a 
70-μm mesh. Human PBMCs were obtained from healthy donors using 
Histopaque 1077 (Sigma-Aldrich). Cells were incubated with mAbs for 
20 min on ice with gentle agitation after 10 min. For blocking experiments, 
cells were incubated with proteins (50 μg/ml mAbs, 9.5 μM MULT1, or 
125 μM ULBP4) for 15 min before the addition of tetramers. Both mono-
biotinyl-BSA and West Nile virus glycoprotein DIII (30) were used for ir-
relevant control tetramers with identical results. Live cell gates were based on 
forward and side scatter plots and 7-amino-actinomycin D fl  uorescence. 
Data were collected on a FACSCalibur (Becton Dickinson) and analyzed 
with FloJo software (TreeStar, Inc.).
Chromium release assays. B6 NK cells stimulated with IL-2 for 7 d were 
  incubated for 10 min with media supplemented with nothing, MULT1, 
OMCPBR, or irrelevant recombinant protein (BSA or West Nile virus glyco-
protein DIII with identical results) at the concentrations indicated in the 
fi  gures. These were used in triplicate 51Cr killing assays, as previously 
described (23).
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